Beijing Tong Ren Tang Chinese Medicine Co Ltd (HK:3613)
:3613
Top Page
Beijing Tong Ren Tang Chinese Medicine Co
(3613)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$9.00
▲(4.53% Upside)
Action:ReiteratedDate:10/18/25
The overall stock score of 59 for Beijing Tong Ren Tang Chinese Medicine Co. is primarily driven by mixed financial performance (score: 60, weight: 50%), with a strong balance sheet offset by significant cash flow concerns. Valuation (score: 70, weight: 20%) provides a positive contribution due to a reasonable P/E ratio and attractive dividend yield, while technical analysis (score: 50, weight: 30%) indicates neutral momentum with no clear trend. Investors should prioritize monitoring cash flow risks.
Positive Factors
Revenue Growth
The company's consistent revenue growth highlights its strong market position and ability to expand its customer base, crucial for long-term success.
Negative Factors
Cash Flow Volatility
Volatile cash flow and lack of recent data can hinder financial planning and investment, potentially impacting operational funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company's consistent revenue growth highlights its strong market position and ability to expand its customer base, crucial for long-term success.
Read all positive factors
Beijing Tong Ren Tang Chinese Medicine Co (3613) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.45B
Dividend Yield4.04%
Average Volume (3M)1.10M
Price to Earnings (P/E)17.8
Beta (1Y)0.69
Revenue Growth24.13%
EPS Growth4.29%
CountryHK
Employees782
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.19
Shares Outstanding837,100,000
10 Day Avg. Volume975,850
30 Day Avg. Volume1,095,238
Financial Highlights & Ratios
PEG Ratio-1.91
Price to Book (P/B)1.80
Price to Sales (P/S)4.56
P/FCF Ratio-28.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.77
Revenue Forecast (FY)HK$1.95B
Beijing Tong Ren Tang Chinese Medicine Co Business Overview & Revenue Model
Company Description
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through thre...
How the Company Makes Money
Beijing Tong Ren Tang generates revenue primarily through the sale of its traditional Chinese medicine products, which include herbal remedies, dietary supplements, and wellness products. Key revenue streams include direct sales from retail outlet...
Beijing Tong Ren Tang Chinese Medicine Co Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
85
Very Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.71B | 1.61B | 1.52B | 1.73B | 1.56B | 1.32B |
| Gross Profit | 1.08B | 1.07B | 1.05B | 1.15B | 1.12B | 952.90M |
| EBITDA | 598.78M | 722.32M | 779.54M | 907.63M | 852.81M | 769.14M |
| Net Income | 515.36M | 500.28M | 540.39M | 645.88M | 607.84M | 542.46M |
Balance Sheet | ||||||
| Total Assets | 4.53B | 4.56B | 4.43B | 4.23B | 3.83B | 3.42B |
| Cash, Cash Equivalents and Short-Term Investments | 2.01B | 1.82B | 2.38B | 2.24B | 2.28B | 1.85B |
| Total Debt | 142.71M | 123.42M | 131.81M | 103.08M | 128.48M | 106.01M |
| Total Liabilities | 312.26M | 313.09M | 413.75M | 486.49M | 295.48M | 287.46M |
| Stockholders Equity | 4.03B | 4.08B | 3.87B | 3.60B | 3.42B | 3.02B |
Cash Flow | ||||||
| Free Cash Flow | 518.75M | -260.42M | 438.96M | 508.94M | 753.74M | 103.17M |
| Operating Cash Flow | 567.10M | -217.25M | 460.83M | 547.44M | 777.17M | 116.05M |
| Investing Cash Flow | -153.66M | 1.35B | -1.08B | 335.41M | -265.73M | 506.73M |
| Financing Cash Flow | -335.60M | -355.30M | -372.18M | -535.42M | -278.65M | -264.30M |
Beijing Tong Ren Tang Chinese Medicine Co Technical Analysis
Negative
8.61
Price Trends
8.59
Negative
8.70
Negative
8.85
Negative
Market Momentum
-0.23
Positive
22.88
Positive
13.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3613, the sentiment is Negative. The current price of 8.61 is above the 20-day moving average (MA) of 8.35, above the 50-day MA of 8.59, and below the 200-day MA of 8.85, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 22.88 is Positive, neither overbought nor oversold. The STOCH value of 13.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3613.
Beijing Tong Ren Tang Chinese Medicine Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$5.15B | 4.25 | 5.98% | 4.47% | 0.73% | -34.04% | |
68 Neutral | HK$6.30B | 12.63 | 14.79% | 2.61% | 16.41% | 32.97% | |
59 Neutral | HK$6.45B | 17.83 | 12.72% | 4.04% | 24.13% | 4.29% | |
59 Neutral | HK$1.68B | 21.20 | 3.91% | ― | -15.96% | 32.95% | |
58 Neutral | HK$9.80B | 35.32 | 7.49% | 4.47% | 1.65% | -16.38% | |
54 Neutral | HK$9.17B | -28.37 | -1.26% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
7.71
-0.48
-5.88%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.82
-0.05
-2.93%
HK:1666
Tong Ren Tang Technologies Co
4.02
-0.56
-12.15%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
2.33
1.91
454.76%
HK:2273
Gushengtang Holdings Limited
26.90
-4.67
-14.79%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.68
1.23
22.57%
Beijing Tong Ren Tang Chinese Medicine Co Corporate Events
Beijing Tong Ren Tang Chinese Medicine Renews Three-Year Master Lease Deal With Controlling Shareholder
Dec 30, 2025
Beijing Tong Ren Tang Chinese Medicine Company Limited has signed a renewed master lease framework agreement with its controlling shareholder, Tong Ren Tang Holdings, to secure the continued leasing of premises used for production and operations f...
Beijing Tong Ren Tang Chinese Medicine Renews PRC Distribution Deal With Controlling Shareholder
Dec 30, 2025
Beijing Tong Ren Tang Chinese Medicine has agreed to renew its PRC distribution framework agreement with its controlling shareholder, Tong Ren Tang Holdings, for a further three-year term from 1 January 2026 to 31 December 2028, ensuring continuit...
Beijing Tong Ren Tang Signs New Trademark Licence Agreement
Nov 28, 2025
Beijing Tong Ren Tang Chinese Medicine Co has announced the termination of its Current Trademark Licence Agreement with Tong Ren Tang Holdings, effective from December 31, 2025. A new agreement, the New Trademark Licence Framework Agreement, has b...
Beijing Tong Ren Tang Announces Q3 2025 Financial Results
Oct 28, 2025
Beijing Tong Ren Tang Chinese Medicine Company Limited announced the unaudited financial results of its controlling shareholder, Tong Ren Tang Technologies Co. Ltd., for the nine months ending September 30, 2025. This disclosure is part of regulat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.